JP6817073B2 - セロトニン受容体を標的にする化合物および方法 - Google Patents

セロトニン受容体を標的にする化合物および方法 Download PDF

Info

Publication number
JP6817073B2
JP6817073B2 JP2016568912A JP2016568912A JP6817073B2 JP 6817073 B2 JP6817073 B2 JP 6817073B2 JP 2016568912 A JP2016568912 A JP 2016568912A JP 2016568912 A JP2016568912 A JP 2016568912A JP 6817073 B2 JP6817073 B2 JP 6817073B2
Authority
JP
Japan
Prior art keywords
compound
receptors
receptor
less
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016568912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017521367A (ja
JP2017521367A5 (enExample
Inventor
ブース,レイモンド,ジー.
Original Assignee
ノースイースタン ユニバーシティ
ノースイースタン ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノースイースタン ユニバーシティ, ノースイースタン ユニバーシティ filed Critical ノースイースタン ユニバーシティ
Publication of JP2017521367A publication Critical patent/JP2017521367A/ja
Publication of JP2017521367A5 publication Critical patent/JP2017521367A5/ja
Application granted granted Critical
Publication of JP6817073B2 publication Critical patent/JP6817073B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/46Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C215/64Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00Systems containing two condensed rings
    • C07C2602/02Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2016568912A 2014-05-19 2015-05-19 セロトニン受容体を標的にする化合物および方法 Active JP6817073B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462000286P 2014-05-19 2014-05-19
US62/000,286 2014-05-19
PCT/US2015/031523 WO2015179366A1 (en) 2014-05-19 2015-05-19 Serotonin receptor-targeting compounds and methods

Publications (3)

Publication Number Publication Date
JP2017521367A JP2017521367A (ja) 2017-08-03
JP2017521367A5 JP2017521367A5 (enExample) 2018-06-28
JP6817073B2 true JP6817073B2 (ja) 2021-01-20

Family

ID=54554616

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016568912A Active JP6817073B2 (ja) 2014-05-19 2015-05-19 セロトニン受容体を標的にする化合物および方法

Country Status (7)

Country Link
US (1) US11021435B2 (enExample)
EP (1) EP3145906B1 (enExample)
JP (1) JP6817073B2 (enExample)
CN (1) CN106573872B (enExample)
BR (1) BR112016027096B1 (enExample)
ES (1) ES2967976T3 (enExample)
WO (1) WO2015179366A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3297979B1 (en) * 2015-05-19 2024-11-20 Northeastern University Compounds and methods for modulating serotonin receptors in the periphery
CN108794308B (zh) * 2017-04-27 2021-07-20 北京大学深圳研究生院 1,2,3,4-四氢萘类化合物及其制备方法和应用
KR20220122602A (ko) * 2019-10-23 2022-09-02 맵라이트 세라퓨틱스, 인크. 자폐 스펙트럼 장애의 증상을 치료하는 방법
KR20230073197A (ko) * 2020-08-19 2023-05-25 노스이스턴 유니버시티 세로토닌 수용체 조절제
CN117730073A (zh) * 2021-07-14 2024-03-19 东北大学 血清素5-ht2a、5-ht2b和5-ht2c受体反向激动剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
GB9509156D0 (en) * 1995-05-05 1995-06-28 Sandoz Ltd Organic compounds
ES2219679T3 (es) 1995-10-18 2004-12-01 Akzo Nobel N.V. Vacuna de combinacion contra la enfermedad de newcastle.
US20030008880A1 (en) * 2001-05-02 2003-01-09 Pfizer Inc. 4-(2-Pyridyl) piperizines having 5HT7 receptor agonist activity
EP1956006A1 (en) * 2007-02-06 2008-08-13 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted-tetrahydro-naphthalen derivatives as 5-HT7 receptor ligands
EP1975161A1 (en) * 2007-03-28 2008-10-01 Laboratorios del Dr. Esteve S.A. Heterocyclyl-substituted- tetrahydro-napthalen-amine derivatives, their preparation and use as medicaments
WO2008154044A1 (en) * 2007-06-15 2008-12-18 University Of Florida Research Foundation Therapeutic compounds and methods of use
US8586634B2 (en) 2007-06-15 2013-11-19 University Of Florida Research Foundation, Inc. Therapeutic compounds
WO2009061436A1 (en) * 2007-11-06 2009-05-14 University Of Florida Research Foundation Compound for activating 5-ht2c receptors in combination with an amphetamine compound
US9024071B2 (en) * 2009-05-05 2015-05-05 University Of Florida Research Foundation, Inc. Therapeutic compounds

Also Published As

Publication number Publication date
BR112016027096A2 (pt) 2018-07-10
US11021435B2 (en) 2021-06-01
EP3145906B1 (en) 2023-10-04
ES2967976T3 (es) 2024-05-06
US20170081273A1 (en) 2017-03-23
EP3145906A4 (en) 2018-01-24
EP3145906A1 (en) 2017-03-29
JP2017521367A (ja) 2017-08-03
CN106573872B (zh) 2021-07-20
BR112016027096B1 (pt) 2023-04-11
WO2015179366A1 (en) 2015-11-26
CN106573872A (zh) 2017-04-19

Similar Documents

Publication Publication Date Title
JP6817073B2 (ja) セロトニン受容体を標的にする化合物および方法
US11111210B2 (en) Phenyl cyclohexanone derivatives and methods of making and using them
IL298769A (en) Benzofuran compounds are useful for mental disorders or mental enhancement
WO2017087858A1 (en) Pyrazole compounds and methods of making and using same
HUE030081T2 (en) Heterocyclic benzodioxole or benzodioxepine compounds as phosphodiesterase inhibitors
TW201002701A (en) Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity
WO2007069565A1 (ja) 二環式複素環化合物
EP3697781B1 (en) Antagonists of the muscarinic acetylcholine receptor m4
MX2015003637A (es) Piridinonas biciclicas novedosas.
AU2019216492A1 (en) Antagonists of the muscarinic acetylcholine receptor M4
JP2023530715A (ja) アリールスルホニル誘導体及びムスカリン性アセチルコリン受容体m5阻害剤としてのその使用
TW200808784A (en) Substituted phenyl methanone derivatives
Banister et al. 7-Azabicyclo [2.2. 1] heptane as a scaffold for the development of selective sigma-2 (σ2) receptor ligands
TW202517609A (zh) 氘化有機化合物及其用途(二)
Llabrés et al. Molecular basis of the selective binding of MDMA enantiomers to the alpha4beta2 nicotinic receptor subtype: synthesis, pharmacological evaluation and mechanistic studies
US20240067611A1 (en) Phenyl cyclohexanone derivatives and methods of making and using them
HK1236024B (en) Serotonin receptor-targeting compounds
HK1236024A1 (en) Serotonin receptor-targeting compounds
CN108727416A (zh) 三环杂芳香体系酰胺衍生物及其制备和用途
ES2892175T3 (es) Moduladores de los receptores NMDA, composiciones que los incluyen y uso de dichos compuestos en el tratamiento de enfermedades que implican al sistema nervioso central
US11827606B2 (en) Phenyl cyclohexanone derivatives and methods of making and using them
CN109890798A (zh) 用于治疗cns病症的羟基去甲氯胺酮衍生物
US20230348358A1 (en) Serotonin Receptor Modulators
WO2023150526A1 (en) Competitive and noncompetitive octahydrocyclopenta[c]pyrrole inhibitors of the muscarinic acetylcholine receptor m5
RS67052B1 (sr) Vmat2 inhibitori i postupci primene

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191111

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201102

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20201124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20201224

R150 Certificate of patent or registration of utility model

Ref document number: 6817073

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250